ABT · News · 20261022N
Guidance / Outlook
ABBOTT LABORATORIES · 2026-10-22 · Importance 47 · Surprise 60 · In source text
Abbott reduced its 2026 guidance during its third-quarter earnings update. RBC attributed the guidance cuts to headwinds in Abbott’s diabetes and electrophysiology portfolios. Management also highlighted competitive pressure in diabetes care and upcoming product launches as near-term execution factors. The revised outlook was discussed alongside the planned Nutrition separation and longer-term portfolio repositioning.
Key facts
- Management addressed reduced revenue growth expectations on the third-quarter 2026 earnings call. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | probable | — | Management addressed reduced revenue growth expectations on the third-quarter 2026 earnings call. |